Dr. Cornelia Haag-Molkenteller M.D., Ph.D. is the Chief Medical Officer of USI, a subsidiary of the Company. From April 2015 to March 2018, Dr. Haag-Molkenteller was the Vice President in Clinical Development at Allergan plc, and from November 2007 to March 2015, the Vice President in Global Drug Development. While at Allergan, she led clinical development of onabotulinumtoxinA (BOTOX) for OAB and neurogenic detrusor overactivity. From 1988 to 2006, she was the Vice President of Clinical Program Leadership at Schwarz Biosciences GmbH. Dr. Haag-Molkenteller earned an M.D. and Ph.D. from Johann Wolfgang Goethe-Universität Frankfurt am Main.
As the Chief Medical Officer of USI of Urovant Sciences Ltd, the total compensation of Cornelia Molkenteller at Urovant Sciences Ltd is $1,703,470. There are no executives at Urovant Sciences Ltd getting paid more.
Cornelia Molkenteller is 61, he's been the Chief Medical Officer of USI of Urovant Sciences Ltd since 2018. There are no older and 6 younger executives at Urovant Sciences Ltd.
Cornelia's mailing address filed with the SEC is C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE, CA, 92617.
Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... a Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.
Urovant Sciences Ltd executives and other stock owners filed with the SEC include: